Advertisement

Clinical Rheumatology

, Volume 34, Issue 4, pp 707–714 | Cite as

HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients

  • Jing Zou
  • Qiang Guo
  • Jiachang Chi
  • Huawei Wu
  • Chunde BaoEmail author
Original Article

Abstract

The aim of this study is to evaluate the factors associated to 1-year mortality in clinically amyopathic dermatomyositis (CADM) patients with acute interstitial lung disease (ILD). A single center of 37 cases of Chinese patients with CADM was reviewed retrospectively in Renji hospital. All CADM patients were diagnosed with ILD; there were 24 cases of acute interstitial pneumonia (AIP) and 13 cases of acute exacerbation of non-acute interstitial pneumonia non-AIP. The clinical features, including blood tests, chest high-resolution computed tomography (HRCT) score, and lung function, were analyzed, respectively. Neutrophil lymphocyte ratio (NLR), serum ferritin level, serum lactate dehydrogenase (LDH) level, and HRCT score were statistically significant factors on univariate analysis. Multivariate analysis revealed that the overall HRCT score (HR 1.134, 95 % confidence interval 1.009–1.275, P = 0.017) and serum ferritin level (HR 1.001, 95 % confidence interval 1.002–1.007, P = 0.010) were independently significant factors of 1-year mortality. C statistic value of HRCT score (c statistic value 0.867, P < 0.0001) and serum ferritin level (c statistic value 0.808, P = 0.002) were statistically significant in the classification of non-survivors. Patients with calcineurin inhibitor presented a better outcome than those without calcineurin inhibitor (log-rank test, P = 0.006). HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute ILD in CADM patients. Calcineurin inhibitor might improve the outcome of CADM patients with acute ILD.

Keywords

Amyopathic dermatomyositis Computed tomography Ferritins Interstitial Lung diseases Mortality 

Notes

Acknowledgments

We are grateful to Masataka Kuwana (Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Japan) for excellent technical assistance in measuring anti-MDA5 antibodies. We would like to thank Dr. Jiachang Chi and Dr. Huawei Wu (Department of Radiology, Ren Ji hospital, School of Medicine, Shanghai Jiao Tong University) for reviewing the chest HRCT image.

Conflict of interest

The authors declare they have no conflicts of interest.

Funding

None.

Authors contribution

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. BCD and ZJ were involved with conception and design; ZJ, CJC, and WHW acquisition of the data; and BCD, ZJ, and GQ analysis and interpretation of the data.

Patient consent

Obtained.

References

  1. 1.
    Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17:701–706CrossRefPubMedGoogle Scholar
  2. 2.
    Ye S, Chen XX, Lu XY et al (2007) Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26:1647–1654CrossRefPubMedGoogle Scholar
  3. 3.
    Sato S, Hirakata M, Kuwana M et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571–1576CrossRefPubMedGoogle Scholar
  4. 4.
    Mukae H, Ishimoto H, Sakamoto N et al (2009) Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136:1341–1347CrossRefPubMedGoogle Scholar
  5. 5.
    Fathi M, Lundberg IE, Tornling G (2007) Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med 28:451–458CrossRefPubMedGoogle Scholar
  6. 6.
    Sontheimer RD (2010) Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol 146:76–80PubMedGoogle Scholar
  7. 7.
    Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine’ myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–636CrossRefPubMedGoogle Scholar
  8. 8.
    Akira M, Hamada H, Sakatani M et al (1997) CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 168:79–83CrossRefPubMedGoogle Scholar
  9. 9.
    Bernard GR, Artigas A, Brigham KL et al (1994) The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824CrossRefPubMedGoogle Scholar
  10. 10.
    Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T et al (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60:2193–2200CrossRefPubMedGoogle Scholar
  11. 11.
    Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J (2008) Fleischner Society: glossary terms for thoracic imaging. Radiology 246:697–722CrossRefPubMedGoogle Scholar
  12. 12.
    Ichikado K, Suga M, Müller NL et al (2002) Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and non-survivors. Am J Respir Crit Care Med 165:1551–1556CrossRefPubMedGoogle Scholar
  13. 13.
    Ichikado K, Suga M, Muranaka H et al (2006) Prediction of prognosis for acute respiratory distress syndrome with thinsection CT: validation in 44 cases. Radiology 238:321–329CrossRefPubMedGoogle Scholar
  14. 14.
    Akobeng AK (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 96:644–647CrossRefPubMedGoogle Scholar
  15. 15.
    Douglas WW, Tazelaar HD, Hartman TE et al (2001) Polymyositis- dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164:1182–1185CrossRefPubMedGoogle Scholar
  16. 16.
    Marie I, Hachulla E, Cherin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614–622CrossRefPubMedGoogle Scholar
  17. 17.
    Lakhanpal S, Lie JT, Conn DL, Martin WJ 2nd (1987) Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 46:23–29CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, Chen PJ (2002) Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 21:391–396CrossRefPubMedGoogle Scholar
  19. 19.
    Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, Colby TV (2007) Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 101:1761–1769CrossRefPubMedGoogle Scholar
  20. 20.
    Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, Hashimoto D, Sato J, Toyoshima M, Hashizume H, Chida K (2006) Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 28:1005–1012CrossRefPubMedGoogle Scholar
  21. 21.
    Ichikado K, Johkoh T, Ikezoe J et al (1997) Acute interstitial pneumonia: high-resolution CT findings correlated with pathology. AJR Am J Roentgenol 168:333–338CrossRefPubMedGoogle Scholar
  22. 22.
    Ichikado K, Suga M, Gushima Y et al (2000) Hyperoxiainduced diffuse alveolar damage in pigs: correlation between thin-section CT and histopathologic findings. Radiology 216:531–538CrossRefPubMedGoogle Scholar
  23. 23.
    Tanizawa K, Handa T, Nakashima R et al (2013) The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 107:745–752CrossRefPubMedGoogle Scholar
  24. 24.
    Gono T, Kawaguchi Y, Hara M et al (2010) Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology 49:1354–1360CrossRefPubMedGoogle Scholar
  25. 25.
    Kotani T, Makino S, Takeuchi T et al (2008) Early intervention with corticosteroids and cyclosporin A and 2-h postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 35:254–259PubMedGoogle Scholar
  26. 26.
    Kotani T, Takeuchi T, Makino S et al (2011) Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 30:1021–1028CrossRefPubMedGoogle Scholar
  27. 27.
    Ando M, Miyazaki E, Yamasue M et al (2010) Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 29:443–445CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2015

Authors and Affiliations

  • Jing Zou
    • 1
  • Qiang Guo
    • 2
  • Jiachang Chi
    • 3
  • Huawei Wu
    • 3
  • Chunde Bao
    • 2
    Email author
  1. 1.Department of Pneumology, Ren Ji Hosptial, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  2. 2.Department of Rheumatology, Ren Ji Hosptial, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  3. 3.Department of Radiology, Ren Ji Hosptial, School of MedicineShanghai Jiao Tong UniversityShanghaiChina

Personalised recommendations